Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. News
  7. Summary
    OCGN   US67577C1053

OCUGEN, INC.

(OCGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Social Buzz: Ocugen, AMC, BlackBerry Top WallstreetBets Stock Gainers at Thursday Close

10/14/2021 | 04:32pm EST


ę MT Newswires 2021
All news about OCUGEN, INC.
11/26FDA Places Clinical Hold on Phase 3 Study for Ocugen COVID-19 Vaccine Covaxin
MT
11/26Health Care Stocks Mixed Pre-Bell Friday
MT
11/26OCUGEN : Provides an Update on its Investigational New Drug Application with U.S. FDA to I..
PU
11/26OCUGEN, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/26OCUGEN : FDA Issues Clinical Hold on Covid-19 Trial; Shares Down
DJ
11/26Ocugen Says US FDA Issued Clinical Hold on its Investigational New Drug Application for..
MT
11/26Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. F..
AQ
11/24Bharat's COVID-19 shot 50% effective at height of India infections - small study
RE
11/18Ocugen Inc.áAnnounces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/15OCUGEN, INC. : Other Events (form 8-K)
AQ
More news
Analyst Recommendations on OCUGEN, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -53,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -21,5x
Yield 2021 -
Capitalization 1 285 M 1 285 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 7,10x
Nbr of Employees 15
Free-Float 97,5%
Chart OCUGEN, INC.
Duration : Period :
Ocugen, Inc. Technical Analysis Chart | OCGN | US67577C1053 | MarketScreener
Technical analysis trends OCUGEN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 6,45 $
Average target price 8,88 $
Spread / Average Target 37,6%
EPS Revisions
Managers and Directors
Shankar Musunuri Chairman & Chief Executive Officer
Sanjay Subramanian CFO, Secretary & Head-Corporate Development
Arun Upadhyay Vice President-Research & Development
Bruce D. Forrest Chief Medical Officer
Uday B. Kompella Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OCUGEN, INC.252.46%1 285
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431